Notice on Convening the 2025 Annual General Meeting
Filed with SSE · · 8 pages · Chinese
Earlier from InnoCare Pharma
- InnoCare Announces Approval of Orelabrutinib for the First-line Treatment of CLL/SLL in China
- InnoCare Announces the Acceptance of New Drug Application for pan-TRK Inhibitor Zurletrectinib in China
- Announcement on Voluntary Disclosure of the Latest Research Results of Multiple Oncology Pipelines Selected for 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
- InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China
- InnoCare Releases 2024 Results and Business Highlights
Later from InnoCare Pharma
- InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA
- Announcement on the Provision of Online Voting Reminder Service for the General Meeting
- InnoCare’s Mesutoclax Receives Breakthrough Therapy Designation from China’s NMPA
- Announcement on Signing Strategic Cooperation Framework Agreement and Scientific Research Cooperation Agreement with Westlake University and Related Party Transactions
- InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China
Follow InnoCare Pharma into a list and get an email when it puts out news.
Follow InnoCare Pharma